SCHEMBL26773320

SCHEMBL26773320

NC(=O)c1nn(-c2c(Cl)cccc2Cl)cc1Nc1ccc(C(=O)N2CCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.47
▸ HPGD P15428 3/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ TYK2 P29597 4/20 0.45
▸ JAK2 O60674 3/20 0.45
▸ JAK1 P23458 3/20 0.45
▸ JAK3 P52333 3/20 0.45
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ GRM5 P41594 5/20 0.43
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ CDK4 P11802 2/20 0.42
▸ CCND1 P24385 2/20 0.42
▸ CCNT1 O60563 1/20 0.42
▸ CDK9 P50750 1/20 0.42
▸ CDK6 Q00534 1/20 0.42
▸ CDK11A Q9UQ88 1/20 0.42
▸ WEE1 P30291 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26777206 0.99 HPGD (0.47) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL26773322 0.99 HPGD (0.47) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL26773315 0.98 TYK2 (0.45) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL30486270 0.93 TYK2 (0.50) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL26773365 0.93 TYK2 (0.50) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL30486259 0.93 TYK2 (0.49) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL26773367 0.93 TYK2 (0.49) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL26773311 0.92 CCNT1 (0.49) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL26773188 0.91 CCNT1 (0.52) MAPTHPGDALDH1A1SMN1; SMN2TYK2
SCHEMBL26773658 0.91 HPGD (0.44) MAPTHPGDALDH1A1SMN1; SMN2TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4192464-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Origenis GmbH (DE) 2023-06-14 — — EP claimed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 MAPT 1519/4885HPGD 4226/4885ALDH1A1 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback